NCT06843252 Home-based TDCS (Transcranial Direct Current Stimulation) for Cognitive and Behavioral Symptoms in Huntington's Disease
| NCT ID | NCT06843252 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Texas Health Science Center at San Antonio |
| Condition | Huntington Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 16 participants |
| Start Date | 2025-09-02 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 16 participants in total. It began in 2025-09-02 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The researchers hope to find out effects of transcranial direct current stimulation (tDCS) sessions on the behavioral symptoms of Huntington's Disease. If participants are eligible to continue, they will be provided a device to administer the tDCS for 30 minutes each day and be asked to answer questions with the study staff . Participants will be asked to return to the study center for follow ups and to undergo additional cognitive tests and questionnaires. Participants will also be asked to answer questionnaires via a web conferencing platform (Zoom) during the course of the study. Caregivers of the participants will be asked to answer questionnaires to collect more information about the participants.
Eligibility Criteria
Inclusion Criteria: 1. individuals aged 18-85 years with confirmed HD mutation and/or established family history alongside typical symptoms (i.e., chorea) of HD; 2. early (stages 1 and 2) or moderate (stage 3) stages according to Shoulson-Fahn criteria, also known as the UHDRS total functional capacity (TFC) scale (Bates, Tabrizi, and Jones 2014); 3. exhibit mild to moderate behavioral symptoms defined by severity scores in the PBA-S between 1 and 3 for any of the evaluated symptoms and no symptoms with a severity score of 4; 4. stable doses of medications for at least one month. 5. Ability of subject to understand and the willingness to sign a written informed consent document. 6. Have a caregiver willing to be present during tDCS sessions and answer questionnaires. Caregiver 1. An adult who serves as an unpaid caregiver for an individual enrolled in the study as interpreted by the PI or delegate physician. 2. Adequate cognitive capacity to provide verbal consent to participate in the caregiver arm of the study. 3. Adequate reading, writing, hearing, and verbal capacity to provide collateral information about the study participant as well as answer questions related to their health and care. Exclusion Criteria: 1. Unstable medical conditions (e.g. unstable angina, uncontrolled diabetes and hypertension, advanced cancer, etc.); 2. History of epilepsy; 3. Clinical diagnosis of major cognitive disorder (i.e., dementia); 4. Have risk of suicidal behavior, defined as any suicidal behavior or suicidal ideation of type 4 (active suicidal ideation with some intent to act, without specific plan) or type 5 (active suicidal ideation with specific plan and intent) based on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the 3 months prior to screening (Posner et al. 2011); 5. Being an active participant in other therapeutic clinical trial; 6. Determined to be incapable of consent per PMH or via assessment by the study staff at time of consent. 7. Participant has a pacemaker or any other implanted device/material contraindicated in the use of tDCS per current labeling requirements. Caregiver 1\. Any individual who does not meet all the inclusion criteria
Contact & Investigator
Thiago Macedo e Cordeiro, MD, MSc
PRINCIPAL INVESTIGATOR
The University of Texas Health Science Center at San Antonio
Frequently Asked Questions
Who can join the NCT06843252 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Huntington Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06843252 currently recruiting?
Yes, NCT06843252 is actively recruiting participants. Contact the research team at macedoecorde@uthscsa.edu for enrollment information.
Where is the NCT06843252 trial being conducted?
This trial is being conducted at San Antonio, United States.
Who is sponsoring the NCT06843252 clinical trial?
NCT06843252 is sponsored by The University of Texas Health Science Center at San Antonio. The principal investigator is Thiago Macedo e Cordeiro, MD, MSc at The University of Texas Health Science Center at San Antonio. The trial plans to enroll 16 participants.